AWS Bahrain Region Disrupted by Drone Activity Amid Middle East Conflict 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
Palestinian Activist Leqaa Kordia Released from U.S. Immigration Detention After Judge's Order 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
Federal Reserve Hires Robert Hur to Fight DOJ Subpoenas Targeting Jerome Powell 
Trump Administration Settles Lawsuit Barring Federal Agencies from Pressuring Social Media Censorship 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Costco Faces Class Action Lawsuit Over Tariff Refunds as Supreme Court Strikes Down Trump's IEEPA Tariffs 
Federal Judge Blocks Trump Administration's Move to End Temporary Protected Status for Somali Immigrants 
The Missouri Supreme Court rejected Johnson & Johnson's appeal of a ruling by the Missouri Court of Appeals awarding $2.12 billion damages to women who blamed the company's asbestos-tainted products for their ovarian cancer.
The New Brunswick, New Jersey-based firm called the verdict a product of fundamentally flawed trial, grounded in a faulty presentation of the facts and vowed to elevate the case to the US Supreme Court.
Johnson & Johnson insists that there were decades of independent scientific evaluations that found their product safe, asbestos-free, and not cancer-causing.
In July 2018, a jury ruled that Johnson & Johnson was liable $4.69 billion to the complainants.
The Missouri Court of Appeals upheld the jury verdict on June 23 but reduced the payout to $2.12 billion after dismissing claims by 22 plaintiffs.
It said that it may be inferred from evidence that the company disregarded consumer safety for profit.
Kevin Parker, a lawyer for the plaintiffs, said that Johnson & Johnson should accept the verdict of the jury and the appellate court and compensate the victims.
Johnson & Johnson said it would set aside a $2.1 billion reserve for the verdict.
The company, which said that it would stop selling its Baby Powder talc in the US and Canada, revealed that it faces over 21,800 lawsuits claiming that its talc products contain asbestos, a known carcinogen.
Johnson & Johnson's baby powder was intensely scrutinized for safety after a 2018 Reuters investigative report said that it knew for decades that about the asbestos contamination of its talc.
Evidence showed that from at least 1971 to the early 2000s,
Johnson & Johnson's raw talc and finished powders have tested positive for small amounts of asbestos.
